Pfizer and Johnson & Johnson's Brewing Brawl Gets Real
Pfizer (NYSE: PFE) took direct aim at Johnson & Johnson (NYSE: JNJ) last year when it won FDA approval for Inflectra, a biosimilar to Johnson & Johnson's multi-billion dollar per year autoimmune disease drug, Remicade.
Remicade's market size made Inflectra's approval arguably the most significant approval yet for biosimilars, however, Inflectra's sales have been growing more slowly than expected, and based on a suit just filed by Pfizer, it's Johnson & Johnson that's to blame for its sluggish start.
Image source: Getty Images.
Source: Fool.com
Merck & Co. Inc. Stock
€104.20
0.000%
With 31 Buy predictions and 1 Sell predictions Merck & Co. Inc. is one of the favorites of our community.
With a target price of 125 € there is a slightly positive potential of 19.96% for Merck & Co. Inc. compared to the current price of 104.2 €.
